Anaveon AG
5
0
2
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
20.0%
1 terminated/withdrawn out of 5 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)
Role: lead
ACT-TIL and ANV419 for Advanced Melanoma.
Role: collaborator
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Role: lead
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
Role: lead
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Role: lead
All 5 trials loaded